171 related articles for article (PubMed ID: 27836057)
1. The Nuts and Bolts of Immunoglobulin Treatment for Antibody Deficiency.
Wasserman RL
J Allergy Clin Immunol Pract; 2016; 4(6):1076-1081.e3. PubMed ID: 27836057
[TBL] [Abstract][Full Text] [Related]
2. Immunoglobulin Replacement Therapy for Primary Immunodeficiency.
Sriaroon P; Ballow M
Immunol Allergy Clin North Am; 2015 Nov; 35(4):713-30. PubMed ID: 26454315
[TBL] [Abstract][Full Text] [Related]
3. Immunoglobulin replacement therapy for primary immunodeficiencies.
Peter JG; Chapel H
Immunotherapy; 2014; 6(7):853-69. PubMed ID: 25290417
[TBL] [Abstract][Full Text] [Related]
4. Human immunoglobulin 10 % with recombinant human hyaluronidase: replacement therapy in patients with primary immunodeficiency disorders.
Sanford M
BioDrugs; 2014 Aug; 28(4):411-20. PubMed ID: 24925799
[TBL] [Abstract][Full Text] [Related]
5. Recombinant human hyaluronidase facilitated subcutaneous immunoglobulin treatment in pediatric patients with primary immunodeficiencies: long-term efficacy, safety and tolerability.
Wasserman RL; Melamed I; Kobrynski L; Puck J; Gupta S; Doralt J; Sharkhawy M; Engl W; Leibl H; Gelmont D; Yel L
Immunotherapy; 2016 Oct; 8(10):1175-86. PubMed ID: 27468136
[TBL] [Abstract][Full Text] [Related]
6. Switching immunoglobulin products, what are the implications? Result of 2018 census of immunology centres.
Bethune C; Herriot R
Clin Med (Lond); 2019 May; 19(3):201-204. PubMed ID: 31092511
[TBL] [Abstract][Full Text] [Related]
7. Managing patients with side effects and adverse events to immunoglobulin therapy.
Azizi G; Abolhassani H; Asgardoon MH; Shaghaghi S; Negahdari B; Mohammadi J; Rezaei N; Aghamohammadi A
Expert Rev Clin Pharmacol; 2016; 9(1):91-102. PubMed ID: 26496172
[TBL] [Abstract][Full Text] [Related]
8. [Prevention and therapy with immunoglobulin SRK].
Schnoz M; Ryser DH; Barandun S; Eckmann L
Helv Chir Acta; 1979 May; 46(1-2):111-3. PubMed ID: 38227
[TBL] [Abstract][Full Text] [Related]
9. Immunoglobulin treatment in primary antibody deficiency.
Maarschalk-Ellerbroek LJ; Hoepelman IM; Ellerbroek PM
Int J Antimicrob Agents; 2011 May; 37(5):396-404. PubMed ID: 21276714
[TBL] [Abstract][Full Text] [Related]
10. [Replacement therapy with subcutaneous immunoglobulin in primary immunodeficiency in children].
Pac M
Pol Merkur Lekarski; 2011 Jun; 30(180):413-6. PubMed ID: 21751550
[TBL] [Abstract][Full Text] [Related]
11. [Use of intravenous and subcutaneous human immunoglobulins].
Ramus B; Benbrahim O; Chérin P
Soins; 2019 Mar; 64(833):13-18. PubMed ID: 30879622
[TBL] [Abstract][Full Text] [Related]
12. Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency.
Wasserman RL; Melamed I; Stein MR; Gupta S; Puck J; Engl W; Leibl H; McCoy B; Empson VG; Gelmont D; Schiff RI;
J Allergy Clin Immunol; 2012 Oct; 130(4):951-7.e11. PubMed ID: 22846381
[TBL] [Abstract][Full Text] [Related]
13. Shift from intravenous or 16% subcutaneous replacement therapy to 20% subcutaneous immunoglobulin in patients with primary antibody deficiencies.
Canessa C; Iacopelli J; Pecoraro A; Spadaro G; Matucci A; Milito C; Vultaggio A; Agostini C; Cinetto F; Danieli MG; Gambini S; Marasco C; Trizzino A; Vacca A; De Mattia D; Martire B; Plebani A; Di Gioacchino M; Gatta A; Finocchi A; Licciardi F; Martino S; De Carli M; Moschese V; Azzari C
Int J Immunopathol Pharmacol; 2017 Mar; 30(1):73-82. PubMed ID: 27927705
[TBL] [Abstract][Full Text] [Related]
14. Pharmacoeconomics of immunoglobulins in primary immunodeficiency.
Simoens S
Expert Rev Pharmacoecon Outcomes Res; 2009 Aug; 9(4):375-86. PubMed ID: 19670998
[TBL] [Abstract][Full Text] [Related]
15. [Subcutaneous immunoglobulin substitution and therapy].
Gulácsy V; Maródi L
Orv Hetil; 2011 Jan; 152(2):64-7. PubMed ID: 21177233
[TBL] [Abstract][Full Text] [Related]
16. [Therapeutic use of immunoglobulins in children (author's transl)].
Hitzig WH
Blut; 1980 Mar; 40(3):215-24. PubMed ID: 6988023
[TBL] [Abstract][Full Text] [Related]
17. Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies.
Dams ET; van der Meer JW
Lancet; 1995 Apr; 345(8953):864. PubMed ID: 7898254
[No Abstract] [Full Text] [Related]
18. [Clinical results with a new intravenous immunoglobulin preparation (author's transl)].
Hansi W; Kratzsch G; Heimpel H
Dtsch Med Wochenschr; 1980 Nov; 105(48):1675-80. PubMed ID: 7439053
[TBL] [Abstract][Full Text] [Related]
19. In-line warming reduces in-line pressure of subcutaneous infusion of concentrated immunoglobulins.
Leidenmühler P; Höfinghoff J; Haider N; Brachtl G; Weiller M; Bilic I; Gangadharan B
Drug Deliv Transl Res; 2023 Sep; 13(9):2367-2377. PubMed ID: 36920736
[TBL] [Abstract][Full Text] [Related]
20. Improved quality of life, immunoglobulin G levels, and infection rates in patients with primary immunodeficiency diseases during self-treatment with subcutaneous immunoglobulin G.
Berger M; Murphy E; Riley P; Bergman GE;
South Med J; 2010 Sep; 103(9):856-63. PubMed ID: 20689467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
